Physician profile
Derek Bast
NPI 1437612272
$1,530.02
in general payments reported to CMS, 2019-2025
18 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.50 · 2020: $98.21 · 2021: $424 · 2022: $450 · 2023: $211 · 2024: $217 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.61 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $238.68 | 2022-2025 | Wegovy, Saxenda |
| Amarin Pharma, INC. | $122.55 | 2023 | |
| Glaxosmithkline, LLC. | $116.88 | 2019-2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.47 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $100.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $74.12 | 2022 | |
| Gilead Sciences, INC. | $52.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.35 | 2022 | |
| Alexion Pharmaceuticals, INC. | $40.44 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.98 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $32.27 | 2024 | Trintellix |
| Pfizer INC. | $25.28 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.70 | 2025 | Spravato |
| Indivior INC. | $14.88 | 2024 | Sublocade |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $14.76 | 2024 | Aristada, Lybalvi |
| Ultragenyx Pharmaceutical INC. | $14.72 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.66 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Bast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.